Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGMB-129 in healthy volunteers
NCT07118878Phase 1Completed
- Sponsor
- Agomab Therapeutics
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing AGMB-129 with Placebo (2 arms). Primary endpoints: Adverse Events at 42 days, Physical Examination Abnormalities at 42 days and 4 more. Started Aug 2025; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07118878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118878.